Dr. Reddy’s Laboratories Limited (NYSE:RDY) Q3 2026 Earnings Call Transcript

Dr. Reddy’s Laboratories Limited (NYSE:RDY) Q3 2026 Earnings Call Transcript January 21, 2026

Dr. Reddy’s Laboratories Limited reports earnings inline with expectations. Reported EPS is $0.16 EPS, expectations were $0.16.

Aishwarya Sitharam: Good day, everyone, and welcome to the Quarter 3 FY ’26 Earnings Call of Dr. Reddy’s Laboratories Limited. We appreciate your continued interest in our company. I’m Aishwarya Sitharam, Head of Investor Relations at Dr. Reddy’s. Joining us today are members of the leadership team. Mr. Erez Israeli, our Chief Executive Officer; and Mr. M.V. Narasimham, MVN, our Chief Financial Officer. Our quarterly financial results have been published earlier today and are available on our website for your reference. We will start today’s call with MVN providing an overview of our financial performance for the quarter. Following that, Erez will share his insights on key business highlights as well as the company’s strategic outlook.

We will then open the floor for questions. All commentary and analysis during this call are based on our IFRS consolidated financial statements. Please note that certain non-GAAP financial measures may also be discussed. Reconciliations to the corresponding GAAP measures are included in our press release. I would like to remind everyone that the safe harbor provisions outlined in our press release today apply to all forward-looking statements made during this call. Before we proceed, I would like to call out a few housekeeping points. [Operator Instructions]. This session is being recorded, and both the audio and transcript will be made available on our website. Please note that this call is the proprietary material of Dr. Reddy’s Laboratories Limited and may not be rebroadcasted or quoted in any media or public forum without prior written permission from the company.

With that, let me hand the call over to MVN to present the financial highlights for the quarter. Over to you, MVN.

Mannam Venkatanarasimham: Thank you, Aishwarya. A warm welcome to all. Thank you for joining us on our Q3 FY ’26 earnings call. It is my pleasure to take you through our financial performance for the quarter. The business delivered a resilient performance in Q3 FY ’26, reporting a 4.4% revenue growth and steady profitability despite product-specific headwinds. The performance reported this quarter was largely attributable to the double-digit growth delivered by our underlying base businesses, excluding Lenalidomide aided by favorable Forex. Reported EBITDA margin, which stood at 23.5% included a onetime provision related to impact of changes in the implied benefit obligations under the new labor law codes in India. Adjusting for this onetime provision, the EBITDA margin was 24.8%.

All financial figures in this section are translated into U.S. dollars using convenience translation rate of INR 89.84, the exchange rate prevailing as of December 31, 2025. Consolidated revenues for the quarter stood at INR 8,727 crores, which is USD 971 million, a growth of 4.4% year-over-year and a decline of 0.9% on a sequential basis. Strong performance across our branded businesses, namely India, emerging markets and the acquired consumer health care business in Nicotine Replacement Therapy. Further supported by favorable currency exchange rate movements was partially offset by lower Lenalidomide sales and continued pricing pressure in the U.S. and Europe Generics. Consolidated gross profit margin for the quarter was at 53.6%, a decrease of 505 basis points year-over-year and 104 basis points sequentially.

Q&A Session

The decline in margins during the quarter was largely on account of lower Lenalidomide sales, price erosion in our unbranded generic businesses, adverse product mix in PSA and the onetime provision related to new labor law codes mentioned earlier. Adjusting for this one-off, the margin was at 54.1%. The reported gross margin was 57.4% for global generics and 17.3% for PSA. The SG&A spend for the quarter was INR 2,692 crores, which is USD 300 million, an increase of 12% on year-over-year and 2% on Q-o-Q. The year-over-year increase was primarily on account of ongoing targeted investment to support long-term growth of our branded franchises, namely the acquired NRT Consumer Healthcare business and branded generics. Adverse Forex impact as well as the onetime provision related to the new labor law codes.

SG&A spend accounted for around 31% of the revenue during the quarter was higher by 199 basis points year-over-year and 82 basis points on a sequential basis. Excluding the one-off provision, SG&A spend as a percentage to the revenue was around 30% in Q3 FY ’26. The R&D spend for the quarter was INR 615 crores, which is USD 68 million, a decline of 8% year-over-year and largely flat sequentially. The decrease reflected lower development spends in biosimilars given that large part of investment related to abatacept have been completed, the spend this quarter also included onetime new labor law codes related to the provision. The R&D spend was 7% of revenues for Q3 FY ’26, lower by 92 basis points on year-over-year and the same level as the previous quarter.

Excluding the on-off R&D spend was at 6.8% of Q3 revenues. Other operating income for the quarter was INR 77 crores as against INR 44 crores in the corresponding quarter last year. EBITDA for the quarter, including other income stood INR 2,049 crores, which is USD 228 million, a decline of 11% on year-over-year basis and 13% sequentially. The EBITDA margin stood at 23.5%, lower by 401 basis points on year-over-year and 322 basis points Q-o-Q. Adjusting for onetime new labor law codes related to the provision, the underlying EBITDA margin was at 24.8%. The net finance income for the quarter was higher at INR 117 crores as compared to net finance expenses of INR 2 crores during the same quarter last year. The increased net finance was primarily on account of higher foreign exchange gain this quarter in comparison to foreign exchange loss reported in the corresponding quarter last year.

As a result, profit before tax for the quarter stood at INR 1,543 crores, that is USD 172 million. PBT as a percentage of revenue was at 17.7%. Excluding the onetime new labor law code-related provision, the PBT margin was at 19%. Effective tax rate for the quarter was at 22.9% compared to 25.1% in the corresponding period last year. The ETR for Q3 FY ’26 was lower primarily due to favorable durational mix for the quarter in comparison to the same period in the previous year. Profit after tax attributable to equity holders of the period for the quarter stood at INR 1,210 crores, which is USD 135 million, a decline of 14% year-over-year and 16% on Q-o-Q. This is at 13.9% of revenue before adjusting the one-off provision related to a new labor law codes.

The diluted EPS for the quarter is INR 14.52. Operating working capital as of 31st December 2025 was INR 14,142 crores, which is a USD 1.57 billion, an increase of INR 811 crores, which is USD 90 million over 30th September 2025. CapEx cash outflow for the quarter stood at INR 669 crores, which is $75 million. Free cash flow generated during the quarter was INR 374 crores, which is $42 million. As of December 31, 2025, we have a net cash surplus of INR 3,069 crores which is equivalent to USD 342 million. Foreign currency cash flow hedges executed through derivative instrument during the period are as follows: USD 481 million hedged using a combination of forwards and structured derivative contracts scheduled to mature through March 2027. The contracts are hedged at the rate of USD 89.1 to USD 90.3. RUB 2.93 billion hedge at a fixed rate of RUB 1.06 with a maturity falling within next 3 months.

With this, I now request Erez to take us through the key business highlights.

Erez Israeli: Thank you so much, MVN. Good day, everyone, and thank you for joining us today. We really appreciate your continued engagement and interest in our company. Thank you all for joining our meeting. Our overall performance in Q3 FY ’26 remain consistent with our strategy. And we continue to deliver on our strategic priorities during the quarter, namely growing the base business, driving gross efficiencies across operations, advancing our key pipeline programs, semaglutide and abatacept as well as pursuing selective business development video opportunities to augment our organic growth efforts. In line with our stated aspirations, our underlying base business delivered overall a double-digit growth this quarter. The company EBITDA margin was about 25%.

And this is adjusted for onetime provision related to the new labor codes in India. Let me now walk you through some of the key highlights of the quarter. Revenue grew by 4.4% year-on-year despite lower contribution from Lenalidomide. Our base business, excluding Lenalidomide, delivered double-digit growth. The overall growth for the quarter was also aided by favorable Forex. EBITDA margin stood at 23.5%, which included a onetime provision related to the new labor codes mentioned earlier, excluding this onetime provision, EBITDA margin is at 24.8%, like I mentioned, about 25%. Annualized ROCE was at 20.4%. Net cash surplus at the end of the quarter was $342 million. In alignment with our strategic focus to deliver a first-in-class and innovative therapies in India and emerging market, we entered into a strategic collaboration with Immutep for commercialization of a novel immunotherapy oncology drug, Eftilagimod Alfa, a key global market outside of North America, Europe and Japan and Greater China with an upfront of $20 million potential regulatory and commercial milestones of up to $350 million as well as royalties.

Further, we recently launched Hevaxin, a novel, recombinant vaccine for the prevention of Hepatitis-E virus infection in India. We are pleased that the integration of the acquired Nicotine Replacement Therapy business is progressing as per plan. 85% of the business by value is now under operational controls. The next phase of integration will include selected countries, Asia Pacific, Middle East and Latin America. We expect integration largely to be completed by the end of this fiscal. We continue to make progress on our key pipeline products. During the quarter, we received a marketing authorization for semaglutide injection in India from DCGI following the recommendation of subject to expert committee in the SEC under Central Drug Standard Control Organization.

Further, necessary local manufacturing license have been secured. We have also started filing in various emerging markets through the COPP route. In October 2025, we received a notice of noncompliance from the Canadian pharmaceutical drug directorate for our semaglutide injection, which outlined a request for additional information and clarification on the specific aspect of the submission. We promptly submitted our response by mid-November 2025, well within the stipulated time and now we are awaiting a response from the regulatory agency in Canada. On the biologics front, we have completed the filing of the biologics license application, the BLA, for the IV presentation of abatacept biosimilar candidate in December 2025 as per the schedule.

Following the positive opinion for CHMP, we received European Commission approval for denosumab biosimilar in Q3 FY ’26. Likewise, we have received the approval from MHRA in the U.K. Our in-house commercial team has launched the product in Germany in December and launched a preparation are underway for the U.K. and other European countries. We received a complete response letter from the USFDA for denosumab biosimilar BLA, which is — was developed by our partner, Alvotech. The CRL refers to the observation from a pre-license inspection of Alvotech, Reykjavík manufacturing facility. On the regulatory front, in November 2025, the USFDA conducted GMP inspection of our API facility CTO-SEZ in Srikakulam, Andhra Pradesh with 0 observations. In December 2025, the USFDA completed a GMP and a preapproval inspection of our facility FTO-SEZ PU-01 in Srikakulam, Andhra Pradesh and issued Form 483 with 5 observations.

We have responded already to the agencies within the stipulated times. Recently, the USFDA issued a post application action letter in relation to the response submitted to the observation received post the PI conducted at our Bachupally biologics facility in September 2025 for our rituximab biosimilars. We are actively working to resolve the outstanding observations. Our CDMO business, Aurigene Pharmaceutical Services Limited served as an exclusive API manufacturer for 2 of the 46 novel drug approved by the USFDA in 2025. Further, APSL delivered 3 discovery programs through its in-house AI-assisted discovery platform called Aurigene.Ai. We continued progress on our industry-leading sustainability practices. During the quarter, we announced a science-based net zero climate target, making us the only Indian pharmaceutical company to commit to such a target by FY ’24 — FY2045.

We are in the leadership position in CDP Water Security & Climate Change categories for 2025. Let me take you to the key business highlights for the quarter. Please note that all financial figures mentioned are reported in the respective local currencies. Our North America Generics business generated revenues of $338 million for the quarter, a decline of 16% year-on-year and 9% sequentially. The decline was primarily on the account of level in Lenalidomide sales and price erosion in certain key products. During the quarter, we continued to launch momentum, adding 6 new products to our portfolio. Our European generic business reported revenue of $140 million for the quarter, a growth of 4% on a year-to-year basis as well as sequentially. The acquired Nicotine Replacement Therapy portfolio, which is now also in the base has been performing well.

Further, new product launches helped offset the impact of price erosion in generics. During the quarter, we launched 10 new generics products across markets, further strengthening our product portfolio. Our emerging market business delivered revenue of INR 1,896 crores in Q3 FY ’26, reflecting a robust growth of 32% year-on-year and 15% sequentially. Growth was primarily driven by new product launches across various markets and favorable Forex. During the quarter, we introduced 30 new products across countries in line with our commitment to improving access and further deepening our market presence. Within this segment, our Russia business delivered growth of 21% year-on-year and 16% sequentially in constant currency terms amid continued adverse macroeconomic conditions.

Our India business reported revenue of INR 1,603 crores in Q3 FY ’26, delivering a healthy double-digit year-on-year growth of 19% and 2% increase sequentially. This performance was attributable to revenues from our innovation franchise, new brand launches price increases and higher volumes as well as contribution from recently acquired Stugeron portfolio. According to IQVIA, we continue to outperform the Indian pharmaceutical market, IPM, with a moving quarterly total mass quarterly, MQT, growth of 12.3% compared to the IPM growth of 11.8% and moving annual total, MAT, growth of 9.7% compared to IPM of 8.9% growth. Our IPM rank is 10 for the quarter and 9 for the month of December 2025. During the quarter, we launched 2 new brands as we continue to enhance our domestic market presence.

Our PSAI business reported revenue of $92 million in Q3 FY ’26, resulting in a decline of 5% year-on-year and 15% sequentially. During the quarter, we filed 31 Drug Master Files globally. In line with our strategic priorities, we remain committed to investing in differentiated R&D programs, especially peptides and biosimilars that offer meaningful commercial opportunities. In addition to our enhanced development efforts, we also — we will also continue to strategically collaborate to build our innovation portfolio for India and emerging markets. During the quarter, we completed 28 global generic filings. As we look forward, our focus remains on effective execution to deliver on our strategic priorities improving base business both advancing differentiated pipeline products like semaglutide, abatacept, driving operational efficiencies and pursuing value-accretive acquisition and partnership aimed at creating long-term value for our stakeholders.

Before we move to the Q&A session, I would like to announce that Aishwarya Sitharam has recently taken over as the Head of Investor Relationship from Richa Periwal. I wish both Aishwarya and Richa, Richa is staying with our organization success in their respective new promoted roles. With that, I welcome your thoughts and questions as we move into the Q&A sessions.

Aishwarya Sitharam: Thank you very much, Erez. [Operator Instructions] The first question is from the line of Neha Manpuria from Bank of America.

Neha Manpuria: I have 2 questions from me. First, on the India business growth. The 19% growth, how should I think about organic growth for the India business because we did have the Stugeron acquisition in this quarter. Was that a meaningful contributor to this 19% growth? If I were to strip that out, would that growth still be, let’s say, north of 15%? Would that be a fair assumption?

Erez Israeli: So it’s somewhere between 17% and 18%, if I calculate, I’m not sure exactly where it is. But let’s say, it’s more than 17% organic without acquisitions.

Mannam Venkatanarasimham: That’s right, Erez.

Neha Manpuria: And what is driving this strong growth? It is because we’ve been doing — I know we’ve been moving in the double-digit category for a few quarters now, but to step up to 17%, 18%, does seem very large in a quarter’s time. What’s changed in this quarter? And how sustainable is this growth trajectory, particularly this, let’s say, mid-teens sort of growth trajectory as we look through the next few quarters?

Erez Israeli: So it’s primarily the performance of the innovative product. So normally, and there are actually very good products that are being really appreciated by the market. So normally, when you produce a brand that is not known, there is a period of time in which you have a cycle of physicians that recognize this product and then recommend it. So there is a certain gross pattern like introduction of any brand. And I think what happens to us is actually the strategy is working. We are in some of these brands in the third year since launch and some of them in the second year. And you will start to see the move of that. So the — in addition to the brand didn’t perform in a similar manner, meaning that we are increasing the prices, we have the support of those, but it’s primarily the — what we called at the time of Horizon 2 introducing of innovation to India, this is the primary move that it’s actually working.

Neha Manpuria: Understood. Sorry, one last question on India. The innovative portfolio would be what portion of our sales roughly today if you were to quantify it?

Aishwarya Sitharam: 15% to 20%…

Erez Israeli: No, it should be less.

Mannam Venkatanarasimham: It should be less.

Erez Israeli: If I need to, it’s somewhere between 10% to 15%, but I’m not sure, Neha.

Neha Manpuria: All right. No problem. And my second question is on sema. I think you mentioned that we have submitted the response, and we are waiting — sorry, we are awaiting response from the agency. So have we not got a follow-up goal date as well? And according to you, what would be the next time line that we should look at for sema approval in Canada?

Erez Israeli: Yes. So we do have a goal date because it’s come automatically 6 months from the response time. So it takes us to May. But it doesn’t mean that we need to get approval by that date, it can be any time between now and May, and hopefully, in May, no additional question. So I’m — I don’t know when we will get a response. We are preparing for a launch even in Q4 and there is scenarios like that. And if not, it will be in Q1. But let’s say, any time between end of February to May, we should expect to launch in Canada.

Aishwarya Sitharam: The next question is from the line of Damayanti Kerai from HSBC.

Damayanti Kerai: My question is again on India business. So you mentioned the innovation — innovative products, et cetera, is helping you to achieve such strong number. So 2 things. Again, I think what is the sustainability of these numbers — growth numbers in India? And also if you can clarify if the December quarter has some spillover benefit from the prior quarter where we had seen the GST disruption?

Erez Israeli: So it’s absolutely sustainable. I don’t know if it’s 90%, which could be also 15%. So it’s absolutely sustainable in this range. And I don’t think that we had a major spillover.

Mannam Venkatanarasimham: There are no spill like on account of GST implementation. This is a clear quarter.

Damayanti Kerai: Got it. My second question is on semaglutide. Again, I guess we are awaiting for Health Canada to revert. But meanwhile, what are your expectations in terms of pricing compared to, say, a few months back, given now most of the companies are, I guess, gearing up for these opportunities? And what’s your broader expectation on the pricing and competition in the key markets where you are looking to launch semaglutide.

Erez Israeli: So expectations did not change much from our recent discussions. We know that eventually, there will be a competition in Canada. We also know that Novo Nordisk announced that they want also to participate, and they even started to offer certain organization in Canada, their — what they call their own generic brands, if you wish, in Canada as well. We have made some arrangements like that. I still believe that if we will get the approval, we have a good chance to be alone or even with a low level of numbers of players that will compete. And over time, they will accumulate the opportunity to my opinion, is still there.

Damayanti Kerai: Sure. And earlier, I guess, your expectation for pricing across different markets where some were say $20 to $70 per unit. So are you still expecting the similar range in terms of pricing in different markets?

Erez Israeli: Yes, yes. The — most of the markets will be on the lower end of the spectrum. But yes, the spectrum is still there. We did not get yet indications that it will be lower. So over time, when people will get approval, we are expecting to be very competitive markets. There will be a short period of time that can be from weeks to months. It depends on the market, in which we can have healthier prices. But then we are preparing ourselves for another very competitive markets.

Damayanti Kerai: So somewhere closer to the lower end of the range, right? That’s the expectation.

Erez Israeli: Yes, yes, yes. I think this is a fair assumption for your analysis.

Aishwarya Sitharam: The next question is from the line of Dr. Bino Pathiparampil from Elara Capital.

Bino Pathiparampil: A couple of questions. One, how much has generic Lenalidomide still contributed to the EBITDA margins in the quarter? And now that we have a visibility of our expense levels, et cetera. What shall we look forward to in terms of EBITDA margins in Q4 and FY ’27?

Erez Israeli: Four years, I did not answer this question. And this is the last quarter that I need to answer this question. So I will not be able to tell you the amount, and this is because of the confidentiality agreement that we have with the innovator. It’s not because I don’t want. But what we can say that the decline that you see in America is primarily Lena. And actually, without Lena, we didn’t grew. So you can take it from there.

Bino Pathiparampil: Got it. When you say decline in the U.S., it’s Y-o-Y or Q-o-Q?

Erez Israeli: Both.

Bino Pathiparampil: And second, can I also understand the time lines now, latest time lines for denosumab and rituximab in the U.S.?

Erez Israeli: Yes. So the denosumab, Alvotech needs to answer the deficiency letter. And then, of course, it depends on how the USFDA will address the response. So the answer is I don’t know, but it is likely that will be in the second quarter of — and maybe even after, of FY ’27. So I’m not expecting it. The normal time that they evaluate the efficiency letter, a new goal date, likely that will take us to this time frame. But I really don’t know because it’s — in biologics, you don’t always end up with 1 deficiency letter. So we need to see. Answer to denosumab — on rituximab, I think you asked for both unless I…

Bino Pathiparampil: Yes. Yes, correct.

Erez Israeli: On rituximab, we have 1 — out of the 2 comments that they gave, which is repeated to our response, it is primarily related to one of the lines of the fill and finish. And on that, we will answer in the next 2 weeks, give or take. And then the expectation that they will come to visit us again and reinspect us. So the approval likely. It’s not official, but I’ll give you my best assessment that likely that we’ll get reinspection on that specific line. And I’m ready preempting one of the next question. There is no impact on abatacept because abatacept is not on the same lines. But this is the task of rituximab. So right now, it will be a response, then they will decide when they want to come to visit, and it will come for there. So unlikely, let’s say, in the next 6 months and maybe more than that.

Aishwarya Sitharam: The next question is from the line of Abdulkader Puranwala from ICICI Securities.

Abdulkader Puranwala: So just firstly, on semaglutide, so I heard your comments about Canada entry in Feb to May where you expect. I mean, how about the other countries in which the patent expires in March, including India? And in terms of — we previously talked about having a capacity of 12 million cartridges. So I mean, is there any increase to that? And by when we should see a meaningful traction coming from this product?

Erez Israeli: So the starting point is India, we will launch on time. The date is March 21. It happened to be my birthday for everybody. So this is one. In Canada, like I mentioned, it can be any time from now until the goal date of May, that’s what I answered Neha. I don’t know exactly in what — in that spectrum, when exactly it’s going to be. But the expectation is that we have an approvable product and we will launch at this time frame. In addition to that, we are using our COPP that we got already for media to register in other markets. Altogether like I mentioned in the past, it’s much more than 80 markets. I think it’s 87 or 80-something markets altogether. But the most meaningful will be Brazil, somewhere around July, as well as Turkey, give or take the same time frame.

In addition to that, we have partners both in India as well as outside of India that wants the right for our semaglutide for their market. And we are obtaining also licensing fee for these kind of activities, not just for this product but also for other products. So that’s overall. So the 12 million pens remains the same for that period of time. For the period after, we can have more than that. Right now, as you know, we are using primarily the fill and finish from Stelis. But as time will go by, we have additional capacity and we continue to use our partner as well as our internal facilities.

Abdulkader Puranwala: Got it. And just to follow up on the biosimilars as well. So what we’re having now a CRL for denosumab and rituximab, so internally, how is that impacting our estimates for your entire biosimilar time lines — launch time lines? And secondly, with abata, is there any time line for launch we are planning internally?

Erez Israeli: Sure. So on rituximab, the main the launch — delay of the launch is to our partner Fresenius. As you recall, rituximab was a product we primarily used to qualify Bachupally. It’s actually served the purpose well. Maybe even too much engagement with the authorities. It’s actually served the purpose really, really well. in that respect. So the launch — overall delay in the launch versus the regional plan is probably a year plus. In Europe, we already launched. So Europe is good, and we are progressing there. They’re also about the same. We launched in Europe, and we are going to launch in additional markets. It’s a very competitive market over there. Denosumab right now because of the efficiency letter, I don’t know exactly when it will answer.

So I don’t know how is the delay, but it is at least 6 months, if not more than that, for this particular product. I don’t see an impact of abatacept. The denosumab is made by a partner, Alvotech in Reykjavík, Iceland, abatacept make on different lines in Bachupally, India. Obviously, we need to get approval for abatacept in the stipulated time. We submitted it on time. So the first expectation is that we’ll get somewhere towards the end of the calendar of ’26, the approval for the IV product and then we can launch it. The approval for the subcu should be by January or February of 2028. We believe that we are still on time for that. Of course, we need to see that we are actually making it happen. But abatacept so far looks in the right direction, especially in the United States.

Aishwarya Sitharam: The next question is from the line of Kunal Dhamesha from Macquarie.

Kunal Dhamesha: Yes. Just one on the sema Canada. Is there a requirement of plant inspection from Health Canada before approval or all those things are already done from our side as well as from our partners side?

Erez Israeli: So no inspections are expected or needed. We just hope for approval. Of course, Kunal, can give us additional queries like a normal regulatory process, but we are expecting approval.

Kunal Dhamesha: But normal regulatory process does not do all plant inspection from Health Canada, like the USFDA has.

Erez Israeli: No, no inspection.

Kunal Dhamesha: Sure, sure. And secondly, no, I think in one of the media articles, the Health Canada spokesperson has kind of mentioned that the manufacturing of the API is different between generic players as well as the — versus the innovator and hence, substitutable status whether the generics would be substitutable as kind of questionable. So if you could provide any color on this, how much confident we are that our generic would be substitutable at the pharmacy level.

Erez Israeli: No, it’s absolutely substitutable. And by the way, what we said is not correct, which actually also the innovator is using synthetic API for the injectables and recombinant products for the oral. And we are planning to do the same for the generics. So in that respect, I don’t see a merit to that statement. I believe the product is absolutely going to be substitutable. So there is no need for a prescription or special processor branding or any branded generic activity. It’s a normal retail products once we’ll get approval.

Kunal Dhamesha: Sure. And my second question is on the new labor code related provision that we have basically provided some INR 117 crores, so how should we think of this? Is it some bit of retrospective cost also baked into this INR 117 crores or it’s just a prospective cost? And is it recurring in nature that structurally, our employee expenses would be a little higher now? How should we think about this?

Mannam Venkatanarasimham: Kunal, as per the new labor law codes now, the wage definition has been revised in line with the new labor law codes, it’s like whoever employees on the payroll of the company as on December 31, we have recomputed retrospectively. It is not like a prospective. So that’s where this entire gratuity leave catchment proportion has been made. And going forward, in line with this may not be this extent, but that would be like my view, less than, I think, 50 basis points, would be the impact, but that’s not very significant.

Aishwarya Sitharam: The next question is from the line of Madhav Marda from Fidelity International.

Madhav Marda: Could you talk a little bit about biosimilar abatacept launch in the European markets as well. Is that something that we are planning to target in the next couple of years? And also, if you could talk about the addressable market in Europe as well? That’s my first question.

Erez Israeli: So yes, sure. So yes, Europe is a very important market for abatacept. We are going to do it by ourselves as well as with partners. The — and we have to cover all the markets because in some of the markets, we don’t have the ability to go to physicians. And so we are trying to cover as much as possible. Obviously, the markets that are tender markets, we can cover easily by ourselves. Likely, that the launch is July.

Mannam Venkatanarasimham: July, we have filed submitting July 2026 and expecting approval by 12 months.

Erez Israeli: Yes. So July 2027, you should expect a launch in Europe.

Mannam Venkatanarasimham: For both IV and the subcu.

Erez Israeli: For both IV and subcu.

Madhav Marda: And how large is the addressable market in Europe for abatacept today?

Erez Israeli: About $2 billion, maybe a little bit more.

Madhav Marda: And is this also in terms of the competitive landscape, given an abatacept seems like we’re the only one who’s completed Phase III, maybe 1 more person is starting off. I don’t know where they are right now. But even in Europe, similar competitive landscape, like we’ll probably be the first only company at launch?

Erez Israeli: Yes. And by the way, the idea is to launch abatacept in every country that has a demand for this product, either by ourselves or with a partner. So the — we are planning to launch at this time frame in Europe, in the United States, in Japan, in Canada and in every market that there is a demand for this product.

Aishwarya Sitharam: The next question is from the line of Shyam Srinivasan from Goldman Sachs..

Shyam Srinivasan: Just the first one on the NRT, the disclosure you have shared around the growth there, right, is about 25% Y-o-Y. Can you split it out into like constant currency and what the growth was? I remember and we had about INR 6 billion — INR 600 crores last year same time, and we had INR 1 billion pretax profits. So how has that evolved even for at these levels now?

Mannam Venkatanarasimham: So Shyam on the constant currency is year-over-year 8% growth.

Shyam Srinivasan: Okay. So the rest is all coming from currency [indiscernible]?

Mannam Venkatanarasimham: Yes.

Shyam Srinivasan: Okay. So how should we look at the steady-state growth for this? Is there something that has changed? Because I remember single-digit growth was what we guided to. So that continues, right, in constant currency?

Erez Israeli: Yes, Shyam, firstly, yes. It can be — right now, we have — we see upside to the model. It’s not a significant upside. But let’s say, instead of — we always said single digit. But right now, it looks like on the upper side of the single digit. And it may go to double-digit depends because we are also participating in certain tenders like Brazil, and other stuff. So if you win this tender, it gives you a chunk of sales in a particular situation. Overall, it looks good. It looks that we are exceeding the expectations that we had internally. And actually, the demand from this product is higher than what we thought.

Shyam Srinivasan: Helpful. So just a subpart of the question was on the profitability as well. As we have — I know we have done additional brand building access, but has the profitability materially changed?

Mannam Venkatanarasimham: Yes. Because of like sales are also higher and then it is like here, the A&P investments overall, if you remember, like at the business case level, we said EBITDA is around 25%. But now since we are doing well, the EBITDA percentage is higher than 25% currently.

Erez Israeli: Going forward, right now, it looks really well above expectations. But let’s say, I think fair assumption will be that we’ll stay with 25%.

Mannam Venkatanarasimham: Yes.

Shyam Srinivasan: Got it. And just the last question to some of the opening remarks you made, Erez, on Novo strategy in Canada. Just curious why would they want to tie up with some local organization? They didn’t file — they didn’t defend their patents originally. Is there a chance that slippage happens across the border into the U.S. for the lower-priced version? Any philosophy or thought process, you’re able to understand why they’re doing it?

Erez Israeli: It’s beyond my paycheck. I’m not managing Novo Nordisk, I hardly manage to read this with a lot of difficulties. I’m assuming that they want to protect their market share. They understand what will happen when a company like us, we launched and other companies we launch. Apparently, it’s important for them to keep the relationship. They also said it, so I’m kind of that. About over the border, probably, but I have no data or indications about it. We are not building on that. Let’s say, we are building on selling to Canadian. And if it will be bought, it will be bought.

Aishwarya Sitharam: The next question is from the line of Tushar Manudhane from Motilal Oswal.

Tushar Manudhane: Thanks for the opportunity. First question on India, semaglutide opportunity. Just would like to understand the approval which we have got is for diabetes and weight management or only diabetes?

Erez Israeli: We got it for the diabetic product. And we are planning to launch eventually all products in India. Also the other part of the products are in the queue to get approval. But what we will launch in March is the generic version of Ozempic, if you wish.

Tushar Manudhane: Got it. And so effectively, if at all for weight management, it would not be in March, but subsequently, as and when you get the approval from the regulatory authority.

Erez Israeli: The physicians will prescribe the way they believe they should. But the indication of the product launch is for diabetic…

Tushar Manudhane: Because the concentration of the product would be relatively — or the strength of the product is relatively lower for weight management, right, in that way?

Erez Israeli: Also, many, many people use the Ozempic for the same. But yes, for the second, the equivalent of Wegovy will come later. In March, we will launch. But in India, we are going to have all strengths. We will have the — both the indication as well as the oral.

Tushar Manudhane: Got it. Sir, secondly, just on this rituximab, let’s say, if at all that reinspection happens post your response. In your experience, has it happened like USFDA accounts only for a particular line for inspection and doesn’t inspect the entire site as such?

Erez Israeli: No, absolutely. It’s this is what PI, pre-approval inspection is all about. So they are coming for a specific line. They can extend it if they wish. It’s up to them. But it’s very, very common, especially on sterile product.

Tushar Manudhane: Got it. And on the same thing, what would be the tentative time line for submitting the subcutaneous version filing for USFDA?

Erez Israeli: Filing time, you guys remember? The subcu for the U.S.

Mannam Venkatanarasimham: U.S. it’s July.

Erez Israeli: July.

Mannam Venkatanarasimham: July 2026.

Erez Israeli: In July, we will submit, and we hope to get the approval and the patent date, which is January or February 2028.

Tushar Manudhane: Got it. And just one more from my side. R&D spend guidance, if you could share?

Erez Israeli: Sorry, what to share?

Aishwarya Sitharam: R&D guidance.

Erez Israeli: R&D guidance…

Mannam Venkatanarasimham: Is in the range of, Tushar, is 7% to 8%, what we have guided earlier. That is — remains same.

Tushar Manudhane: But sir, now that major product, I guess, it was with respect to [indiscernible] largely done. So you think that we will be still on the higher side of this guidance, at least for FY ’27?

Mannam Venkatanarasimham: So because like pembro also, we have just started the collaboration with Alvotech. I think there’s new molecules also we’ll continue to introduce. That’s why we are saying 7% to 8% range.

Erez Israeli: When we have — we finish a budget of products, we obviously want to develop more products. We have aspiration to launch hundreds of products in the next 15 years. So there is enough products to develop. So it’s more how much we can afford in a particular time in our capacity in R&D.

Aishwarya Sitharam: The next question is from the line of Vivek Agrawal from Citi.

Vivek Agrawal: My question is related to SG&A spend. That continues to remain high. And this is against the company’s guidance of some moderation ahead of Revlimid cliff. I just want to understand the outlook here. Are we expecting any kind of decline in SG&A spend next year in FY ’27? Or is it or it can still grow Y-o-Y maybe at a lower rate. So if you can help us understand.

Mannam Venkatanarasimham: Well, Vivek, if you see like at lower Lena sales for the quarter and our — as a percentage to the sales is SG&A still is like without this labor law codes impact at 30%. And then in this 30% also the way which like ForEx has given the favorable impact on the top line, here also like where our SG&A spend also there in Russia, in Europe for the NRT, there is a — like a ForEx impact also is the SG&A. So considering and also we are continuing to invest. I think if you look at like how our branded business as growth be it India, emerging markets, NRT, all are on the solid part of growth. And despite we have continued to invest and then a 30% of the sales, we believe I think we are in the control of the overall SG&A.

Vivek Agrawal: Understood. And that makes sense. But just want to understand an absolute level, right? So in absolute terms, are we expecting any kind of moderation or decline in next year? Or it can still grow from here on?

Erez Israeli: So you’ll see that it will be — it will grow less, so moderation of the growth. The reason for that, as — and we discussed it in the past, we want — and we obviously prepared for the post Lena era for quite some time. We knew it is coming. We are aware of the implications — it’s not — it did not come as a surprise to us. And part of our cost containment, which is one of the key principles that I mentioned is that we want to control the cost. So also the SG&A, the idea is that, overall, the discretionary costs we are controlling very much like we discussed in the past. And the pace of the growth of the cost will be less than half of the growth of the top line.

Aishwarya Sitharam: The next question is from the line of Kunal Lakhan from CLSA.

Kunal Lakhan: My question was on the emerging markets, especially Russia, we saw some good growth numbers this quarter. And I do read your commentary that it’s primarily driven by new product launches. Just wanted to understand how much of this growth was because of the new products and how much was the base business growth here?

Erez Israeli: It is both. It is both. And then — so we have growth in all 3 segments in Russia, meaning the retail, the hospitals and retail, both on the Rx and OTC. So it’s both the old product as well as new products.

Kunal Lakhan: And also in terms of pipeline of new products, if you can give some color on the — in the coming quarters and years, how does the pipeline look like? And is there this growth is sustainable once the current high base is actually in the base?

Erez Israeli: So the growth in Russia is sustainable. Not always, you’ll see a 21% growth every quarter, but double digit — healthy double digit in Russia is absolutely sustainable.

Aishwarya Sitharam: The next question is from the line of Shashank Krishnakumar from Emkay Global.

Shashank Krishnakumar: Just one question on our sema tablets filing in India. I think the SEC has asked for some on-site verification of our Phase III trial data. Now is it something that could — does it typically meaningfully impact approval time lines? Or is it sort of relatively easier to address? I just wanted to understand that.

Erez Israeli: I don’t have any concerns on this one.

Shashank Krishnakumar: Got it. That’s — and just a related question. So post-March, subject to an approval, there’s no litigation overhang even for the launch of tablets, right, in India?

Erez Israeli: Correct.

Aishwarya Sitharam: The next question is from the line of Surya Patra from PhillipCapital.

Surya Patra: Yes. My first question is on the Aurigene CDMO opportunity that in the opening remarks, you have mentioned that it has been qualified as an exclusive supplier of 2 innovative APIs. So how important this opportunity be for us? And when of that we fructifying? And how important or in terms of the revenue contribution that we should be seeing out of it?

Erez Israeli: So as we speak, this is still a small business. We — as I’m sure you all recall, we started the CDMO efforts in a more, let’s say, with — let’s say, more emphasis on this activity for the last 2 years. What we try to do is to engage meaningful products and get — initially, we started with Phase I, Phase II. And we are very happy that effort has started about 2 years ago and now started to yield. How significant it is now? It’s not that significant, but we should absolutely see, I believe, $100-plus million coming to us as a growth in the next 2 to 3 years from that. From the overall scheme, it’s not big for, but for the CDMO business, it is an important place because it will allow them to have sustainable capabilities over time.

Surya Patra: Sure. My second question is on the Lenalidomide, so knowing the fact that we are an integrated player means having our own API also for that. So given that situation, what is the kind of tail end opportunities in the Lenalidomide that we should be seeing?

Erez Israeli: We’ll continue to be in the product. But given the fact that we are comparing it to the period of time which we had this agreement, I always advise the people not to give a value to it. So it will not confuse all of you. So you should assume that the old arrangements from Q4 is 0. Doesn’t mean that we will not sell, but let’s say, just for…

Mannam Venkatanarasimham: Another generic, another molecule…

Erez Israeli: As for clarity, just it will help everybody.

Surya Patra: Sure, sure. Just one booking question. We have talked about the ForEx element in the couple of line items this quarter. So whether there is a kind of a net positive impact that we have seen in what are the kind of a net Forex loss or gain that we have seen in the financials for the quarter? And the same number if you can give for the corresponding previous quarter also?

Mannam Venkatanarasimham: Follow-up in the Erez — Surya, if you see that, I think for each of the sales we have called out, especially in the Europe and EM. Definitely, there’s a ForEx element. At the same time, in the SG&A as well as COGS, whether we import also we ought to account at a higher price. There is a net-net if you ask and then there’s a positive impact on the EBITDA margins.

Surya Patra: Sure. Are we quantifying, sir?

Mannam Venkatanarasimham: I think we haven’t. Not that it’s significant, I think, because I don’t know if there were several…

Erez Israeli: It is not that significant. I don’t remember exactly the numbers, but it is not — like it’s not very significant for the second. It’s — I don’t remember exactly the percentage, but it’s not huge.

Mannam Venkatanarasimham: Yes.

Aishwarya Sitharam: In the interest of time, we will take one last question from Foram Parekh from Bank of Baroda Capital Markets.

Foram Parekh: My question is on the India market. So with the new acquisition that we have done, we have seen growth expanding to 19%. So in FY ’27, can we assume with sema launch and as the new acquisition scales up, would it be wise to assume a growth rate higher than the current growth rate of 19%?

Erez Israeli: I will not — I think you should — we feel very, very comfortable with 15% plus. Can it be more than 19% it can, but I don’t recommend to use it for now. What we can say that the 50%, 60% is very sustainable. The rest is depending on certain scenarios, but it might. Plus, we are not done with BD. So likely the things will come, but of course, we cannot guide for it.

Foram Parekh: Okay. That’s helpful. My second question is on the European side, ex of NRT where we have seen sales mellowing down to 15% growth even with the launch of biosimilars. So again, the question is, as these biosimilars scales up and probably with the launch of abatacept in the European market. So can European region, ex of NRT scale north of 20% or so?

Erez Israeli: Again, it can, but it depends on the scenarios. So the — I think what I can say about Europe, and this is something that we are very proud of in 2018, we had less than EUR 100 million above sales in Europe. And in the future, in the next 2 or 3 years, we will see 10x this number. So it’s emphasized the importance of euro for us. Europe is not only what we do in Europe, so what we do with partners in Europe. So it’s very, very important for us because we will not have capability in all the markets. So the answer is it’s possible if it is possible. We are not guiding for that. What we are saying is that all markets should grow double digit besides the United States that will grow single digit, and this is without taking the impact of Lena. Like I mentioned from next quarter, this arrangement is done and that’s how we should see.

Foram Parekh: Sure. And last question is on the Global Generics gross margin. As REVLIMID sales have come down, we’re seeing gross margins also coming down to 57%, so from next quarter onwards, with 0 REVLIMID sales, can the gross margin territory scale down further?

Mannam Venkatanarasimham: So we can expect without Lenalidomide scenario from Q4 onwards. Our gross margin of both Global Generics and PSA in the range of 50% to 55% because some quarters depends upon the products and business mix, it vary, but the range is like 50% to 55% is the range.

Aishwarya Sitharam: That was the last question for the call today. Thank you all for joining us. We value your time and participation on the call. If you have any further questions or need additional information, please do feel free to reach out to me. With that, we conclude today’s earnings call. Thank you, everybody.

Erez Israeli: Thank you.

Mannam Venkatanarasimham: Thank you, guys.